首页 | 本学科首页   官方微博 | 高级检索  
     


Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction
Authors:Atsushi Nagasaka  Yoshiya Yamamoto  Ken Furuya  Kenichi Kumagai  Minoru Uebayashi  Katsumi Terashita  Tomoe Kobayashi  Izumi Tsunematsu  Manabu Onodera  Takashi Meguro  Megumi Kimura  Jun Ito  Machiko Umemura  Takaaki Izumi  Naoki Kawagishi  Masatsugu Ohara  Yuji Ono  Masato Nakai  Mitsuteru Natsuizaka  Kenichi Morikawa  Koji Ogawa  Naoya Sakamoto  for the NORTE Study Group
Affiliation:1. Sapporo City General Hospital, Hokkaido, Japan;2. Hakodate City General Hospital, Hokkaido, Japan;3. JCHO Hokkaido Hospital, Hokkaido, Japan;4. Hakodate Medical Association Hospital, Hokkaido, Japan;5. Japanese Red Cross Kitami Hospital, Hokkaido, Japan;6. Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan;7. Kushiro Rosai Hospital, Hokkaido, Japan;8. Tomakomai City Hospital, Hokkaido, Japan;9. Touei Hospital, Hokkaido, Japan;10. NTT EAST Sapporo Hospital, Hokkaido, Japan;11. Hokkaido Gastroenterology Hospital, Hokkaido, Japan
Abstract:
Keywords:direct‐acting antiviral  hepatitis C virus  renal impairment  ribavirin  sofosbuvir
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号